Morningstar lifts fair value for Galderma stock to CHF 135.00

Published on 10/26/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morningstar lifted its fair value to CHF 135.00 on October 23, 2026. Galderma stock costs EUR 206.50 on October 26, 2026.

Fair value and market position

Morningstar lifted its Galderma fair value from CHF 130.00 to CHF 135.00 on October 23, 2026.
Third-quarter revenue rose 26.00 percent at constant exchange rates, while nine-month revenue reached USD 4.77 billion.
Galderma stock costs EUR 206.50 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST.
Morningstar cited a 63.68 price-to-earnings ratio and a CHF 44.7 billion market capitalization as of October 26, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (ISIN CH1335392721) was assigned a higher fair value of CHF 135.00 by Morningstar on October 23, 2026, up from CHF 130.00. The research firm kept its cautious view on valuation while highlighting the company revenue performance. Galderma stock was trading at EUR 206.50 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST.

Morningstar raises the valuation bar

According to Morningstar, the fair value increase followed third-quarter revenue growth of 26.00 percent at constant exchange rates and results that exceeded company-compiled consensus by 6.00 percent. Morningstar also cited the higher 2026 sales-growth outlook of 22.50 percent to 23.50 percent, compared with the former range of 19.00 percent to 21.00 percent.

Revenue growth meets a demanding valuation

The operating figures remain substantial. Galderma generated USD 4.77 billion of revenue in the first nine months of 2026, an increase of 25.10 percent at constant exchange rates. In the third quarter, revenue reached USD 1.63 billion, compared with USD 1.57 billion expected by analysts, according to Yahoo Finance.

Price position and valuation

Galderma shares traded on SIX at CHF 191.85 on October 26, 2026 at 5:46 p.m. CEST. The 52-week range was CHF 136.30 to CHF 193.90, placing the price CHF 2.05 below the high. Market capitalization stood at CHF 44.7 billion and the price-to-earnings ratio at 63.68 as of October 26, 2026.

What dates matter next?

MarketScreener reported on October 22, 2026 that Galderma expected the ZO Skin Health transaction to close in the fourth quarter of 2026 or early 2027, while a new United States regulatory filing for Relfydess was targeted for the first quarter of 2027. The company agreed to acquire ZO Skin Health for USD 1.5 billion in cash, a transaction that Morningstar said could weigh modestly on the 2027 core EBITDA margin, according to MarketScreener.

Market context for Galderma

For investors, the central tension is visible in the gap between operating momentum and valuation. Revenue growth of 25.10 percent for the first nine months supports the higher fair value, while the 63.68 price-to-earnings ratio leaves less room for execution setbacks. The company is listed on SIX under ticker GALD.

Stock price and investor perspective

Galderma stock was trading at EUR 206.50 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST. The SIX quotation was CHF 191.85 at 5:46 p.m. CEST on the same date, while the 52-week high stood at CHF 193.90.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.